



## Executive summary of Cardio Renal Metabolic Joint Working Outputs

Published on [Working with the NHS \(astrazeneca.co.uk\)](https://www.astrazeneca.co.uk/working-with-the-nhs)

<b>Project title</b>	Supporting improvements in patient outcomes by optimising medicine adherence in Asthma patients through the introduction of Turbu+, a digital intervention.
<b>Duration</b>	1 <sup>st</sup> July 2019 to 31 <sup>st</sup> December 2020
<b>Project partners</b>	NHS Greater Glasgow & Clyde (NHS GGC) and AstraZeneca UK Limited ("AZ").
<b>What was the issue to be addressed?</b>	<p>The Joint Working Project will:</p> <p>Identify in Primary Care, through pre-agreed criteria, those Asthma patients who may have poor adherence to prescribed inhaled maintenance treatment and may benefit from introducing a digital intervention.</p> <p>The digital intervention to be used is Turbu+, designed to be used with a Symbicort Turbohaler inhaler.</p>
<b>What were the results?</b>	Due to operational challenges, including changes in the Health & Social Care Partnership (HSCP) infrastructure and the COVID-19 pandemic, this project terminated early and failed to deliver any results. c100 patients had enrolled, and c300 devices were provided to NHS Greater Glasgow & Clyde.